Maintenance — sustained metabolic flexibility

Chapters 1 through 9 were the intervention. This chapter is the rest of your life. The work you did over ten weeks rebuilt insulin signaling, retrained mitochondrial fuel flexibility, and reset the G-L-P 1 axis. The practitioner corpus is unambiguous on what happens next if you do nothing: abrupt discontinuation reverses most of it. Studies tracked in the substrate show patients who fully exit G-L-P 1 therapy quickly regain most of their weight and lose almost all of the other health benefits — blood sugar, blood pressure, inflammatory markers. This is not a failure of the protocol. It is a feature of the biology. METABOLIC MEMORY at the receptor, mitochondrial, and hormonal level is real but fragile — it requires a sustaining signal, just at a fraction of the intervention-phase intensity. [short pause] The maintenance protocol is built around three principles the corpus returns to repeatedly. First, the MINIMUM EFFECTIVE DOSE of any G-L-P 1 agent is dramatically lower than the loss-phase dose. Second, mitochondrial peptides cycle — they do not run forever. And third, the foundation compounds — the FOREVER STACK — are the four you stay on indefinitely because their mechanism never desensitizes. [short pause] What stays on, what cycles, what comes off. G-L-P 1 and G-I-P receptor agonists, tirzepatide and semaglutide, do not behave like training adaptations — receptor expression and the appetite-regulating brain circuitry they recruit depend on sustained ligand exposure. The substrate frames the maintenance phase as titrating down to the lowest dose that holds glycemia and weight stable. For most patients exiting the ten-week phase at five to ten milligrams tirzepatide weekly, the maintenance window described in the corpus sits at two point five to five milligrams weekly — a fifty to seventy-five percent reduction. This is not a taper to zero. It is a permanent low-signal floor. [short pause] MOTS-c is the opposite case. The corpus is explicit: twelve weeks on, four weeks off. Unlike BPC-157, which can run indefinitely, MOTS-c requires CYCLING to prevent A-M-P-K receptor desensitization and maintain metabolic responsiveness. Run it continuously and the A-M-P-K signal flattens — you lose the very mitochondrial biogenesis effect you ran the protocol for. The maintenance cadence is one twelve-week cycle every sixteen weeks: roughly three cycles per year. [short pause] Methylene Blue at the pharmaceutical-grade dose — point five to one milligram daily, oral, in the morning — is in the forever category. The substrate flags it as five days on, two days off, long-term safe at this dose. Critical: the pharmaceutical dose is not the ten to fifteen milligram doses circulated online. The substrate is explicit that higher doses flip the dose-response curve from beneficial to harmful. The two-day weekly washout is not for safety — it is to prevent the mitochondrial machinery from down-regulating its own electron transport optimization. [short pause] N-A-D plus support runs forever, but the vehicle changes. The loss-phase N-M-N and 5-Amino-1MQ stack drops to a maintenance rhythm. N-M-N continues at intervention dose because its mechanism — precursor supply — cannot desensitize. 5-Amino-1MQ cycles because its mechanism — N-N-M-T enzyme inhibition — benefits from intermittent pressure rather than continuous blockade. The corpus notes that running both creates a net positive N-A-D plus balance that neither achieves alone — the maintenance phase preserves this synergy at lower intensity. [short pause] The maintenance stack, in detail. Tirzepatide: two point five to five milligrams, subcutaneous, weekly, clinical tier — the lowest dose that holds HbA1c under five point seven percent and weight stable, re-titrate up only if drift is documented over eight weeks. MOTS-c: five to ten milligrams, subcutaneous, two to three times per week, fasted, twelve weeks on and four weeks off, expert tier — three cycles per year, cycling is non-negotiable because continuous use desensitizes A-M-P-K. Methylene Blue, pharma-grade: point five to one milligram, oral, morning, five days on and two off, expert tier — start at point five milligrams, assess after five days, only increase to one milligram if effects are absent, never exceed one milligram without supervision. N-M-N: five hundred milligrams to one gram, oral, daily in the morning, expert tier — N-A-D plus precursor whose mechanism does not desensitize, run indefinitely. 5-Amino-1MQ: fifty to one hundred milligrams, oral, daily for ten to twenty days per cycle, paired with MOTS-c cycles, experimental tier — N-N-M-T inhibition plus lipolysis support, cycle alongside MOTS-c, off during the MOTS-c washout. N-A-D plus subcutaneous: fifty to one hundred milligrams, one to two times weekly, expert tier — the bypass-the-gut alternative to oral precursors during high-stress weeks or post-illness, a substrate-described home protocol. And BPC-157: two hundred fifty to five hundred micrograms, subcutaneous, daily or five days on and two off, expert tier — a forever-stack member, gut lining maintenance keeps incretin signaling intact and protects against G-L-P 1-related G-I fragility. [short pause] The resistance-training and protein-intake layer is not optional and not aesthetic. The corpus is explicit that ANABOLIC RESISTANCE — the same meal that worked for you years ago may not have the same impact today — accelerates on G-L-P 1 therapy because appetite suppression silently drives protein under-eating. Maintenance baseline: one point six to two point two grams of protein per kilogram of lean body mass per day, with resistance training at minimum thirty percent of one-rep max, three sessions weekly. The substrate flags that even bodyweight or light-load training can build significant strength — equipment access is not a valid exit. Without this layer, the maintenance compound stack cannot preserve the muscle insulin sensitivity you spent ten weeks rebuilding. [short pause] What you should feel — months four through twenty-four. Months four through six: energy stable across the day, no afternoon crash, fasting glucose holding eighty to ninety-five mg/dL without effort. Months six through twelve: body composition shifting toward more lean mass — scale weight may rise two to four pounds while waist circumference holds or drops. Months twelve and beyond: HbA1c stable in the five point zero to five point four percent range, fasting insulin under six uIU/mL, and hs-CRP under point eight mg/L sustained. These are the substrate-cited markers of a maintenance phase that is actually working — not just preventing regression but allowing slow continued recomposition. [short pause] And what is NOT happening yet. You are not off all compounds. The substrate is direct: G-L-P 1 discontinuation in trial populations produces quick weight regain and loss of nearly all other health benefits. The maintenance dose IS the protocol, not a transition off it. You are not increasing tirzepatide unless you have eight weeks of documented drift. Single-week glucose spikes or scale fluctuations are noise. Re-titrate on trend, not on panic. You are not running MOTS-c continuously. Continuous A-M-P-K activation is not more aggressive — it is self-defeating. The four-week washout IS the mechanism, not a pause. You are not chasing higher methylene blue doses. One milligram is the ceiling without clinical supervision. The substrate is explicit that the dose-response curve inverts above this. You are not in active intervention. The mental shift from ten-week sprint to indefinite low-signal floor is the hardest part of the protocol. The compounds are easier than the identity change. And you are not done with labs. Quarterly fasting insulin, HbA1c, hs-CRP, and a comprehensive metabolic panel are the minimum maintenance cadence. The substrate flags fasting insulin as the LEADING indicator — watch it before HbA1c moves. [short pause] The corpus describes a maintenance phase, not a finish line. The signal stays on, just quieter. Track it. Adjust.